期刊文献+

磷酸二酯酶与心血管疾病的研究进展 被引量:4

Research advances in phosphodiesterases and cardiovascular diseases
下载PDF
导出
摘要 磷酸二酯酶(PDE)是一类调节cAMP/cGMP活性的超家族酶系。不同的PDE亚型在心血管系统的组织分布和细胞定位不同,所司的功能也不同。该文介绍了与心血管疾病相关的PDE1、PDE3、PDE4和PDE5亚型的分子结构、功能、生物学活性及其与动脉粥样硬化、肺动脉高压、心衰等心血管疾病的关系;探讨了选择性PDE抑制剂在治疗心血管疾病中的应用前景。 Cyclic nucleotide phosphodiesterases(PDE)are gene superfamily enzymes modulating cAMP/cGMP activities, PDE subtypes are different in tissue distribution, cell localization, function and activity regulation in cardiovascular system. This paper introduces the molecular structure, function and biological activity of PDE1, PDE3, PDE4 and PDE5 and their relationship with cardiovascular diseases such as atherosclerosis, pulmonary hypertension and heart failure. Besides, the prospect of selective PDE inhibitors in the treatment of cardiovascular diseases is also discussed.
出处 《上海交通大学学报(医学版)》 CAS CSCD 北大核心 2009年第2期216-219,共4页 Journal of Shanghai Jiao tong University:Medical Science
基金 国家自然科学基金(30540420525)~~
关键词 磷酸二酯酶 分子结构 功能 生物学活性 心血管疾病 phosphodiesterases molecular structure function biological activity cardiovascular diseases
  • 相关文献

参考文献28

  • 1Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents [ J ]. Pharmacol Ther, 2006, 109 (3) :366 - 398. 被引量:1
  • 2Kim D, Rybalkin SD, Pi X, et al. Upregulation of phospho- diesterase 1A1 expression is associated with the development of nitrate tolerance [ J ]. Circulation, 2001, 104 ( 19 ) : 2338 - 2343. 被引量:1
  • 3Yanaka N, Kurosawa Y, Minami K, et al. cGMP-phosphodiesterase activity is up-regulated in response to pressure overload of rat ventricles[ J]. Biosci Biotechnol Biochem, 2003, 67 (5): 973 - 939. 被引量:1
  • 4Rybalkin SD, Rybalkina I, Beavo JA, et al. Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation [ J ]. Cir Res, 2002,90 ( 2 ) : 151 - 157. 被引量:1
  • 5Masunaga R, Nagasaka A, Sawai Y, et al. Changes in cyclic nucleotide phosphodiesterase activity and calmodulin concentration in heart muscle of cardiomyopathic hamsters [ J ]. J Mol Cell Cardial, 2004, 37 (3) : 767 - 774. 被引量:1
  • 6Kostic MM, Erdogan S, Rena G, et al. Altered expression of PDE1 and PDE4 cyclic nucleotide phosphodiesterase isoforms in 7-oxo- prostacyclin-preconditioned rat heart[ J]. J Mol Cell Cardiol, 1997, 29 (11): 3135-3146. 被引量:1
  • 7Dunkerley HA, Tilley DG, Palmer D, et al. Reduced phosphodies-terase 3 activity and phosphodiesterase 3A level in synthetic vascular smooth muscle ceils: implications for use of phosphodiesterase 3 inhibitors in cardiovascular tissues [ J]. Mol Pharmacol, 2002, 61 (5) : 1033 -1040. 被引量:1
  • 8MacKenzie SJ, Baillie GS, McPhee I, et al. Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 ( UCR1 ) [ J]. Br J Pharmacol, 2002, 136 (3) : 421 -433. 被引量:1
  • 9Goncharova EA, Billingtou CK, Irani C, et al. Cyclic AMP2 mobilizing agents and glucocorticoids modulate human smooth muscle cell migration [ J]. Am J Respir Cell Mol Biol, 2003, 29 (1): 19 -27. 被引量:1
  • 10Wagner RS, Smith CJ, Taylor AM, et al. Phosphodiesterase inhibi- tion improves agonist-induced relaxation of hypertensive pulmonary arteries[ J]. J Pharmacol Exp Ther, 1997, 282 (3) : 1650 - 1657. 被引量:1

同被引文献35

  • 1刘丽娟,王强,高修仁.磷酸二酯酶Ⅲ抑制药的临床应用及进展[J].新医学,2006,37(10):677-679. 被引量:48
  • 2Lugnier C.Cyclic nucleotide phosphodiesterase (PDE) superfamily:a new target for the development of specific therapeutic agents[J].Pharmacolo Ther,2006,109(3):366-398. 被引量:1
  • 3Jeon YH,Heo YS,Kim CM,et al.Phosphodiesterase:overview of protein structures,potential therapeutic applications and recent progress in drug development[J].Cell Mol Life Sci,2005,62(11):1198-1220. 被引量:1
  • 4Omori K,Kotera J.Overview of PDEs and their regulation[J].Circ Res,2007,100(3):309-327. 被引量:1
  • 5Giembycz MA,Field SK.Roflumilast:first phosphodiesterase 4 inhibitor approved for treatment of COPD[J].Drug Des Devel Ther,2010,4:147-158. 被引量:1
  • 6Hatzelmann A,Morcillo EJ,Lungarella G,et al.The preclinical pharmacology of roflumilast--a selective,oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease[J].Pulm Pharmacol Ther,2010,23(4):235-256. 被引量:1
  • 7van den Berge M,ten Hacken NH,et al.Small airway disease in asthma and COPD:clinical implications[J].Chest,2011,139(2):412-423. 被引量:1
  • 8Kroegel C,Wirtz H.History of guidelines for the diagnosis and management of asthma:from opinion to control[J].Drugs,2009,69(9):1189-1204. 被引量:1
  • 9Bateman ED,Hurd SS,Barnes PJ,et al.Global strategy for asthma management and prevention:GINA executive summary[J].Eur Respir J,2008,31(1):143-178. 被引量:1
  • 10Jin SL,Goya S,Nakae S,et al.Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma[J].J Allergy Clin Immunol,2010,126(6):1252-1259. 被引量:1

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部